Skip to main content

Table 1 Basal characteristics of healthy and end-stage renal disease (ESRD) hemodialysis patients with targeted and with increased immunoreactive parathyroid hormone (iPTH)

From: The association of secondary hyperparathyroidism and myocardial damages in hemodialysis end-stage renal disease patients: assessed by cardiovascular magnetic resonance native T1 mapping

 

Healthy subjects

(n = 30)

ESRD with targeted iPTH (n = 32)

ESRD with increased iPTH(n = 40)

P

Age (years)

48.1 ± 11.6

58.2 ± 13.9

57.4 ± 15.0

0.06

Gender (Male, n)

12(40.0%)

12(37.5%)

15(37.5%)

0.54

Height (cm)

152.8 ± 7.9

154.8 ± 23.1

156.5 ± 6.5

0.41

Weight (kg)

53.6 ± 6.6

50.3 ± 3.2

53.3 ± 9.6

0.47

Heart rate (beats/min)

71 ± 9

81 ± 12

78 ± 13

0.08

Duration of dialysis (M)

N/A

12–132

9–228

0.06

Duration of renal insufficiency (M)

N/A

12–156

12–228

0.06

Systolic BP

N/A

136 ± 26

142 ± 20

0.34

Diastolic BP

N/A

82 ± 13

89 ± 17

0.24

Causes of ESRD

    

 Polycystic kidney disease (n, %)

N/A

4(12.5%)

6(15.0%)

N/A

  Primary glomerular nephropathy (n, %)

N/A

23(44.3%)

29(55.8%)

N/A

 Vasculitis (n, %)

N/A

1(3.1%)

3(7.5%)

N/A

 Genitourinary tuberculosis (n, %)

N/A

2(6.3%)

4(10.0%)

N/A

  1. Values are mean ± SD or n (%)
  2. M months, BP blood pressure, ESRD End-stage renal disease, CKD chronic kidney disease, iPTH immunoreactive parathyroid hormone